Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Blankenstein, Thomas Prof. Dr. (23) Daniel, Peter Prof. Dr. (1) Jarosch, Ernst Dr. (6) Kammertöns, Thomas Dr. (6) Kopp, Joachim Dr. (2) Leisegang, Matthias Prof. Dr. rer. nat. (2) Nguyen, Tam Hoai Dr. (1) Pezzutto, Antonio Prof. Dr. (3) Quensel, Christina Dr. (1) Selbach, Matthias Prof. Dr. (1) Sommer, Thomas Prof. Dr. (13) (-) Uckert, Wolfgang Prof. Dr. (5) (-) Willimsky, Gerald Dr. (5) Epigenetische Regulation und Chromatinstruktur (18) (-) Intrazelluläre Proteolyse (1) Molekulare Herz- Kreislaufforschung (1) (-) Molekulare Immunologie und Gentherapie (10) Pancreatic Organoid Research and Disease Modeling (1) Proteom Dynamik (1) RNA Biologie und Posttranscriptionale Regulation (1) Systembiologie von Gen-regulatorischen Elementen (3) Translationale Onkologie solider Tumore (1) Zelluläre Neurowissenschaften (1) Zellzustände und ihre Funktionsweisen (1) 1997 (1) 1998 (1) 2000 (3) 2002 (3) 2003 (4) (-) 2004 (2) 2005 (8) 2006 (1) 2007 (3) 2008 (3) (-) 2010 (5) (-) 2011 (3) 2013 (5) (-) 2014 (1) 2015 (2) 2016 (2) 2017 (2) 2018 (5) 2019 (2) 2021 (1) 2022 (2) 2023 (2) 11 Ergebnisse: Active Filter: Uckert, Wolfgang Prof. Dr.Willimsky, Gerald Dr.Intrazelluläre ProteolyseMolekulare Immunologie und Gentherapie 2004201020112014 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. Januar 2004 / Mol Cell Vpu-mediated degradation of CD4 reconstituted in yeast reveals mechanistic differences to cellular ER-associated protein degradation B. Meusser T. Sommer 01. Juli 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein 15. März 2010 / J Immunol In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance C. Buschow J. Charo K. Anders C. Loddenkemper A. Jukica W. Alsamah C. Perez G. Willimsky T. Blankenstein 15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens 15. April 2010 / Clin Cancer Res T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy M. Leisegang A. Turqueti-Neves B. Engels T. Blankenstein D.J. Schendel W. Uckert E. Noessner 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 01. September 2010 / Eur J Immunol Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo S. Shalapour K. Deiser O. Sercan J. Tuckermann K. Minnich G. Willimsky T. Blankenstein G.J. Haemmerling B. Arnold T. Schueler 16. Dezember 2010 / Oncogene The immune response to sporadic colorectal cancer in a novel mouse model M. Czeh C. Loddenkemper S. Shalapour C. Schoen S. Robine E. Goldscheid H. Stein T. Schueler G. Willimsky T. Blankenstein 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. Januar 2004 / Mol Cell Vpu-mediated degradation of CD4 reconstituted in yeast reveals mechanistic differences to cellular ER-associated protein degradation B. Meusser T. Sommer
01. Juli 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein
15. März 2010 / J Immunol In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance C. Buschow J. Charo K. Anders C. Loddenkemper A. Jukica W. Alsamah C. Perez G. Willimsky T. Blankenstein
15. Januar 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
15. April 2010 / Clin Cancer Res T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy M. Leisegang A. Turqueti-Neves B. Engels T. Blankenstein D.J. Schendel W. Uckert E. Noessner
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
01. September 2010 / Eur J Immunol Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo S. Shalapour K. Deiser O. Sercan J. Tuckermann K. Minnich G. Willimsky T. Blankenstein G.J. Haemmerling B. Arnold T. Schueler
16. Dezember 2010 / Oncogene The immune response to sporadic colorectal cancer in a novel mouse model M. Czeh C. Loddenkemper S. Shalapour C. Schoen S. Robine E. Goldscheid H. Stein T. Schueler G. Willimsky T. Blankenstein
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel